Nice Vasso.I'm going to throw in a Q123 MSV guess of $140m-$145m... which would be a solid increase over Q122's $101m.What is everyone else predicting?
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%